Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04924114 · ClinicalTrials.gov registry record · Phase 1
A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT04924114 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 57 participants.
The verdict
NCT04924114, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of MK-6194 in participants with active UC.
Interventions
- DRUG MK-6194
- DRUG MK-6194-matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2021-10-14 |
| Est. Completion | 2024-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04924114
The ClinicalTrials.gov registry entry for NCT04924114 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MK-6194 is the first listed.
NCT04924114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04924114 about?
NCT04924114 is a clinical study titled "A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of MK-6194 in participants with active UC.
What is the current status of trial NCT04924114?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2021-10-14. Estimated completion is 2024-07-15.
What interventions are being tested in trial NCT04924114?
The interventions under investigation include: MK-6194 (DRUG), MK-6194-matching placebo (DRUG).
Who is sponsoring clinical trial NCT04924114?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.